Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron | B3 | Healthcare | Biotechnology & Medical Research | R$337.23B | 13.4x | 0.86 | R$55.28 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | B3 | Healthcare | Biotechnology & Medical Research | R$156.89B | -44.4x | -1.5 | R$53.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings BDR | B3 | Healthcare | Biotechnology & Medical Research | R$147.61B | 19.3x | 7.18 | R$214.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | B3 | Healthcare | Biotechnology & Medical Research | R$129.10B | -25.7x | 0.19 | R$34.29 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | B3 | Healthcare | Biotechnology & Medical Research | R$58.99B | -26.1x | -0.78 | R$64.76 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | B3 | Healthcare | Biotechnology & Medical Research | R$54.05B | -2.8x | -0.07 | R$7.12 | -8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioTechne | B3 | Healthcare | Biotechnology & Medical Research | R$43.09B | 47.4x | -1.7 | R$9.12 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomm On | B3 | Healthcare | Biotechnology & Medical Research | R$1.26B | -15.6x | -0.48 | R$9.85 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |